Skip to main content

PRESS RELEASES

Date Title  
05/28/20
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 28, 2020-- Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present a corporate overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 3 at 10:30 a.m. ET . A live audio webcast of the presentation will be available
05/18/20
– Data from SER-109 Phase 3 study in recurrent C. difficile infection expected mid-2020 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 18, 2020-- Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will host a virtual webcast symposium focused on SER-109 as a potential new therapeutic option
05/07/20
– Data from Phase 3 study of SER-109 in recurrent C. difficile infection expected mid-2020; Potential to be the single pivotal study supporting product registration with the FDA – – Webcast SER-109 investor event to be held May 27 – – Conference call at 8:30 a.m. ET today – CAMBRIDGE, Mass.
04/30/20
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 30, 2020-- Seres Therapeutics, Inc . (Nasdaq: MCRB) today announced that management will host a conference call and live audio webcast on May 7, 2020 at 8:30 a.m. ET to discuss first quarter 2020 results and provide a general business update.
04/06/20
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 6, 2020-- Seres Therapeutics, Inc. , (Nasdaq: MCRB) today announced the appointment of Lisa von Moltke , M.D., FCP, as Executive Vice President and Chief Medical Officer. Dr. von Moltke joins Seres with an extensive career that includes senior leadership
03/30/20
 – Topline ECOSPOR III Phase 3 study data readout timing as planned for mid-2020 – – Potential for ECOSPOR III to be a single pivotal study supporting product registration with FDA – – Company assessing the impact of COVID-19 on SER-287, SER-401 and SER-301 clinical development programs –
03/23/20
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 23, 2020-- Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the appointment of Paul Biondi , Executive Partner at Flagship Pioneering, to its Board of Directors. Noubar Afeyan , Ph.D., a co-founder of Seres and Chief Executive Officer of Flagship
03/15/20
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Seres Therapeutics, Inc . (NASDAQ: MCRB) today announced that it will present at the virtual Chardan Microbiome Medicines Summit on Monday, March 16 at 8:15 a.m. ET . An audio webcast of the presentation will be available under the “Investors and Media” section
03/13/20
FDA alert is related to unapproved fecal microbiota transplantation (FMT) and does not impact Seres’ investigational microbiome therapeutic candidates CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Seres Therapeutics, Inc. (Nasdaq: MCRB) today provided a statement on a safety alert from the U.S.
03/02/20
– Data-rich period ahead including two expected late-stage microbiome clinical readouts: SER-109 in recurrent C. difficile infection in mid-2020 and SER-287 for ulcerative colitis in H2 2020 – – Clinical development activities initiated for SER-301, a next-generation, rationally designed product

Back to top